Drugs.com - Clinical Trials

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop...

Mar 5, 2025 - 21:15
 0
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop...
Read More

Tags:

Previous Article

All Eyes on Eyes at Milan Fashion Week

Next Article

Kenvue Settles Proxy Fight With Activist Starboard

Related Posts

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis

Nipocalimab Granted U.S. FDA Priority Review for the Tr...

Feb 9, 2025  0

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)

Sapience Therapeutics Receives FDA Orphan Drug Designat...

Feb 9, 2025  0

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor VVD-159642 for Treatment of Advanced Solid Tumors

Vividion Therapeutics Doses First Patient in Phase I St...

Apr 8, 2025  0